<table class="drug-table data-table table table-condensed table-bordered"><tbody><tr id="identification"><th class="divider" colspan="2">Identification</th></tr><tr><th>Name</th><td><strong>Salsalate</strong></td></tr><tr><th>Accession Number</th><td><strong>DB01399</strong></td></tr><tr><th>Type</th><td>small molecule</td></tr><tr><th>Groups</th><td>approved</td></tr><tr><th>Description</th><td><p>Salsalate is a nonsteroidal anti-inflammatory agent for oral administration. Salsalate&#8217;s mode of action as an anti-inflammatory and antirheumatic agent may be due to inhibition of synthesis and release of prostaglandins. The usefulness of salicylic acid, the active in vivo product of salsalate, in the treatment of arthritic disorders has been established. In contrast to aspirin, salsalate causes no greater fecal gastrointestinal blood loss than placebo. Salsalate is readily soluble in the small intestine where it is partially hydrolyzed to two molecules of salicylic acid. A significant portion of the parent compound is absorbed unchanged and undergoes rapid esterase hydrolysis in the body. The parent compound has an elimination half-life of about 1 hour. Salicylic acid (the active metabolite) biotransformation is saturated at anti-inflammatory doses of salsalate. Such capacity limited biotransformation results in an increase in the half-life of salicylic acid from 3.5 to 16 or more hours.</p></td></tr><tr><th>Structure</th><td><div class="structure"><a class="moldbi-thumbnail" href="http://structures.wishartlab.com/molecules/DB01399/image.png"><img alt="Thumb" src="http://structures.wishartlab.com/molecules/DB01399/thumb.png"></a></div><div class="structure-links"><div class="btn-group btn-group-xs"><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB01399.mol">MOL</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB01399.sdf">SDF</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB01399.pdb">PDB</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB01399.smiles">SMILES</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB01399.inchi">InChI</a><a class="btn btn-info" href="/structures/structures/small_molecule_drugs/DB01399">View Structure</a></div></div></td></tr><tr><th>Synonyms</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="synonyms"><thead><th>Synonym</th><th>Language</th><th>Code</th></thead><tbody><tr><td>salicylsalicylic acid</td><td><span class="wishart wishart-not-available">Not Available</span></td><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><td>Salsalatum</td><td>Latin</td><td>INN</td></tr><tr><td>Sasapyrine</td><td><span class="wishart wishart-not-available">Not Available</span></td><td><span class="wishart wishart-not-available">Not Available</span></td></tr></tbody></table></td></tr><tr><th>Salts</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Brand names</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="brands"><thead><tr><th>Name</th><th>Company</th></tr></thead><tbody><tr><td>Disalcid</td><td><span class="wishart wishart-not-available">Not Available</span></td></tr></tbody></table></td></tr><tr><th>Brand mixtures</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Categories</th><td><ul><li><a href="/mesh/anti-inflammatory-agents-non-steroidal">Anti-Inflammatory Agents, Non-Steroidal</a></li></ul></td></tr><tr><th>CAS number</th><td>552-94-3</td></tr><tr><th>Weight</th><td>Average: 258.2262<br>Monoisotopic: 258.05282343</td></tr><tr><th>Chemical Formula</th><td>C<sub>14</sub>H<sub>10</sub>O<sub>5</sub></td></tr><tr><th>InChI Key</th><td>WVYADZUPLLSGPU-UHFFFAOYSA-N</td></tr><tr><th>InChI</th><td><div class="wrap">InChI=1S/C14H10O5/c15-11-7-3-1-5-9(11)14(18)19-12-8-4-2-6-10(12)13(16)17/h1-8,15H,(H,16,17)</div></td></tr><tr><th>IUPAC Name</th><td><div class="wrap">2-[(2-hydroxyphenyl)carbonyloxy]benzoic acid</div></td></tr><tr><th>SMILES</th><td><div class="wrap">OC(=O)C1=CC=CC=C1OC(=O)C1=CC=CC=C1O</div></td></tr><tr><th>Mass Spec</th><td><a href="/system/mass_specs/DB01399.gif?1265922772">show</a>(7.76 KB)</td></tr><tr id="taxonomy"><th class="divider" colspan="2">Taxonomy</th></tr><tr><th>Kingdom</th><td>Organic Compounds</td></tr><tr><th>Superclass</th><td>Phenylpropanoids and Polyketides</td></tr><tr><th>Class</th><td>Depsides and Depsidones</td></tr><tr><th>Subclass</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Direct parent</th><td>Depsides and Depsidones</td></tr><tr><th>Alternative parents</th><td>Salicylic Acids; Phenol Esters; Benzoic Acid Esters; Benzoic Acids; Benzylethers; Phenol Ethers; Benzoyl Derivatives; Phenols and Derivatives; Alkyl Aryl Ethers; Carboxylic Acid Esters; Polyols; Enols; Polyamines; Carboxylic Acids; Enolates</td></tr><tr><th>Substituents</th><td>hydroxybenzoic acid; salicylic acid or derivative; salicylic acid; benzoate ester; phenol ester; benzoic acid; benzoic acid or derivative; benzylether; benzoyl; phenol ether; phenol derivative; alkyl aryl ether; benzene; carboxylic acid ester; polyol; ether; carboxylic acid derivative; enol; carboxylic acid; enolate; polyamine</td></tr><tr><th>Classification description</th><td>This compound belongs to the depsides and depsidones. These are polycyclic compounds that is either a polyphenolic compound composed of two or more monocyclic aromatic units linked by an ester bond (depside), or a compound  contaning the depsidone structure (depsidone).</td></tr><tr id="pharmacology"><th class="divider" colspan="2">Pharmacology</th></tr><tr><th>Indication</th><td>For relief of the signs and symptoms of rheumatoid arthritis, osteoarthritis and related rheumatic disorders.</td></tr><tr><th>Pharmacodynamics</th><td>Salsalate is a nonsteroidal anti-inflammatory agent for oral administration. Salsalate's mode of action as an anti-inflammatory and antirheumatic agent may be due to inhibition of synthesis and release of prostaglandins. The usefulness of salicylic acid, the active in vivo product of salsalate, in the treatment of arthritic disorders has been established. In contrast to aspirin, salsalate causes no greater fecal gastrointestinal blood loss than placebo.</td></tr><tr><th>Mechanism of action</th><td>The mode of anti-inflammatory action of salsalate and other nonsteroidal anti-inflammatory drugs is not fully defined, but appears to be primarily associated with inhibition of prostaglandin synthesis. This inhibition of prostaglandin synthesis is done through the inactivation of cyclooxygenase-1 (COX-1) and COX-2, which are reponsible for catalyzing the formation of prostaglandins in the arachidonic acid pathway. Although salicylic acid (the primary metabolite of salsalate) is a weak inhibitor of prostaglandin synthesis in vitro, salsalate appears to selectively inhibit prostaglandin synthesis in vivo, providing anti-inflammatory activity equivalent to aspirin and indomethacin. Unlike aspirin, salsalate does not inhibit platelet aggregation.</td></tr><tr><th>Absorption</th><td>Salsalate is insoluble in acid gastric fluids (</td></tr><tr><th>Volume of distribution</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Protein binding</th><td>Salicylate: 90-95% bound at plasma salicylate concentrations 400 mcg/mL.</td></tr><tr><th>Metabolism</th><td class="data-table-container"><p>Salsalate is readily soluble in the small intestine where it is partially hydrolyzed to two molecules of salicylic acid. A significant portion of the parent compound is absorbed unchanged and undergoes rapid esterase hydrolysis in the body.</p></td></tr><tr><th>Route of elimination</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Half life</th><td>The parent compound has an elimination half-life of about 1 hour. Salicylic acid (the active metabolite) biotransformation is saturated at anti-inflammatory doses of salsalate. Such capacity limited biotransformation results in an increase in the half-life of salicylic acid from 3.5 to 16 or more hours.</td></tr><tr><th>Clearance</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Toxicity</th><td>Death has followed ingestion of 10 to 30 g of salicylates in adults, but much larger amounts have been ingested without fatal outcome.</td></tr><tr><th>Affected organisms</th><td><ul><li>Humans and other mammals</li></ul></td></tr><tr><th>Pathways</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>SNP Mediated Effects</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>SNP Mediated Adverse Drug Reactions</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr id="admet"><th class="divider" colspan="2">ADMET</th></tr><tr><th>Predicted ADMET features</th><td class="data-table-container"><table class="table table-condensed table-striped" id="predicted-admet">
  <thead>
    <tr>
      <th>Property</th>
      <th>Value</th>
      <th>Probability</th>
    </tr>
  </thead>
  <tbody>
      <tr>
        <td>Human Intestinal Absorption</td>
        <td>
              +
        </td>
        <td>0.9161</td>
      </tr>
      <tr>
        <td>Blood Brain Barrier</td>
        <td>
              +
        </td>
        <td>0.8946</td>
      </tr>
      <tr>
        <td>Caco-2 permeable</td>
        <td>
              +
        </td>
        <td>0.5186</td>
      </tr>
      <tr>
        <td>P-glycoprotein substrate</td>
        <td>
            Non-substrate
        </td>
        <td>0.6391</td>
      </tr>
      <tr>
        <td>P-glycoprotein inhibitor I</td>
        <td>
            Non-inhibitor
        </td>
        <td>0.8819</td>
      </tr>
      <tr>
        <td>P-glycoprotein inhibitor II</td>
        <td>
            Non-inhibitor
        </td>
        <td>0.9074</td>
      </tr>
      <tr>
        <td>Renal organic cation transporter</td>
        <td>
            Non-inhibitor
        </td>
        <td>0.8788</td>
      </tr>
      <tr>
        <td>CYP450 2C9 substrate</td>
        <td>Non-substrate</td>
        <td>0.7946</td>
      </tr>
      <tr>
        <td>CYP450 2D6 substrate</td>
        <td>Non-substrate</td>
        <td>0.9353</td>
      </tr>
      <tr>
        <td>CYP450 3A4 substrate</td>
        <td>Non-substrate</td>
        <td>0.7281</td>
      </tr>
      <tr>
        <td>CYP450 1A2 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.7887</td>
      </tr>
      <tr>
        <td>CYP450 2C9 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.5411</td>
      </tr>
      <tr>
        <td>CYP450 2D6 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.9409</td>
      </tr>
      <tr>
        <td>CYP450 2C19 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.8028</td>
      </tr>
      <tr>
        <td>CYP450 3A4 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.9568</td>
      </tr>
      <tr>
        <td>CYP450 inhibitory promiscuity</td>
        <td>Low CYP Inhibitory Promiscuity</td>
        <td>0.8116</td>
      </tr>
      <tr>
        <td>Ames test</td>
        <td>
          Non AMES toxic 
        </td>
        <td>
            0.9731
        </td>
      </tr>
      <tr>
        <td>Carcinogenicity</td>
        <td>
          Non-carcinogens 
        </td>
        <td>
            0.8579
        </td>
      </tr>
      <tr>
        <td>Biodegradation</td>
        <td>
          Ready biodegradable 
        </td>
        <td>
            0.5723
        </td>
      </tr>
      <tr>
        <td>Rat acute toxicity</td>
        <td>
          2.4607 
            LD50, mol/kg
        </td>
        <td>
            <span class="wishart wishart-not-available">Not applicable</span>
        </td>
      </tr>
      <tr>
        <td>hERG inhibition (predictor I)</td>
        <td>
          Weak inhibitor 
        </td>
        <td>
            0.9607
        </td>
      </tr>
      <tr>
        <td>hERG inhibition (predictor II)</td>
        <td>
          Non-inhibitor 
        </td>
        <td>
            0.9403
        </td>
      </tr>
  </tbody>
</table>
</td></tr><tr id="pharmacoeconomics"><th class="divider" colspan="2">Pharmacoeconomics</th></tr><tr><th>Manufacturers</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Packagers</th><td><ul><li><a href="http://www.3m.com">3M Health Care</a></li>
<li>Advanced Pharmaceutical Services Inc.</li>
<li><a href="http://www.amarincorp.com">Amarin Pharmaceuticals</a></li>
<li><a href="http://www.amerisourcebergen.com">Amerisource Health Services Corp.</a></li>
<li><a href="http://www.amneal.com">Amneal Pharmaceuticals</a></li>
<li>Apotheca Inc.</li>
<li><a href="http://www.aqpharmaceuticals.com">AQ Pharmaceuticals Inc.</a></li>
<li><a href="http://orders.a-smeds.com">A-S Medication Solutions LLC</a></li>
<li><a href="http://www.bocapharmacal.com">Boca Pharmacal</a></li>
<li><a href="http://www.caraco.com">Caraco Pharmaceutical Labs</a></li>
<li>Comprehensive Consultant Services Inc.</li>
<li>DHHS Program Support Center Supply Service Center</li>
<li>Direct Dispensing Inc.</li>
<li><a href="http://www.drxdispensing.com">Dispensing Solutions</a></li>
<li><a href="http://www.dhscorp.com">Diversified Healthcare Services Inc.</a></li>
<li><a href="http://www.gsms.us">Golden State Medical Supply Inc.</a></li>
<li><a href="http://hjharkinscompanyinc.com">H.J. Harkins Co. Inc.</a></li>
<li>Heartland Repack Services LLC</li>
<li><a href="http://www.innoviantpharmacy.com">Innoviant Pharmacy Inc.</a></li>
<li>Ivax Pharmaceuticals</li>
<li>Kaiser Foundation Hospital</li>
<li>Lake Erie Medical and Surgical Supply</li>
<li>Liberty Pharmaceuticals</li>
<li><a href="http://www.majorpharmaceuticals.com">Major Pharmaceuticals</a></li>
<li><a href="http://www.unitdosesupply.com">Murfreesboro Pharmaceutical Nursing Supply</a></li>
<li><a href="http://www.nucarerx.com">Nucare Pharmaceuticals Inc.</a></li>
<li><a href="http://www.pdrx.com">PD-Rx Pharmaceuticals Inc.</a></li>
<li><a href="http://www.pharmedixrx.com">Pharmedix</a></li>
<li><a href="http://www.physicianstotalcare.com">Physicians Total Care Inc.</a></li>
<li><a href="http://www.pliva.com">Pliva Inc.</a></li>
<li>Prepackage Specialists</li>
<li><a href="http://www.prepaksys.com">Prepak Systems Inc.</a></li>
<li>Professional Co.</li>
<li><a href="http://www.ranbaxy.com">Ranbaxy Laboratories</a></li>
<li><a href="http://www.rebelrx.com">Rebel Distributors Corp.</a></li>
<li><a href="http://www.remedyrepack.com">Remedy Repack</a></li>
<li>Resource Optimization and Innovation LLC</li>
<li><a href="http://www.sandhillspackaging.com">Sandhills Packaging Inc.</a></li>
<li>Schwarz Pharma Inc.</li>
<li><a href="http://www.southwoodhealthcare.com">Southwood Pharmaceuticals</a></li>
<li><a href="http://sunrisepharma.3gex.com">Sunrise Pharmaceutical Inc.</a></li>
<li>Superior Pharmeceuticals</li>
<li><a href="http://www.urlpharma.com">United Research Laboratories Inc.</a></li>
<li>Va Cmop Dallas</li></ul></td></tr><tr><th>Dosage forms</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="dosages"><thead><tr><th>Form</th><th>Route</th><th>Strength</th></tr></thead><tbody><tr><td>Tablet</td><td>Oral</td><td></td></tr></tbody></table></td></tr><tr id="spectra"><th class="divider" colspan="2">Spectra</th></tr><tr><th>Spectra</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr id="interactions"><th class="divider" colspan="2">Interactions</th></tr><tr><th>Drug Interactions</th><td class="data-table-container"><table class="table table-condensed table-striped" id="experimental-properties"><thead><tr><th>Drug</th><th style="width: 75%"></th></tr></thead><tbody><tr><td><a href="/drugs/DB00443">Betamethasone</a></td><td>The corticosteroid, betamethasone, may decrease the effect of the salicylate, salsalate.</td></tr><tr><td><a href="/drugs/DB00672">Chlorpropamide</a></td><td>The salicylate, salsalate, increases the effect of the sulfonylurea, chlorpropamide.</td></tr><tr><td><a href="/drugs/DB01234">Dexamethasone</a></td><td>The corticosteroid, dexamethasone, may decrease the effect of the salicylate, salsalate.</td></tr><tr><td><a href="/drugs/DB00687">Fludrocortisone</a></td><td>The corticosteroid, fludrocortisone, may decrease the effect of the salicylate, salsalate.</td></tr><tr><td><a href="/drugs/DB01120">Gliclazide</a></td><td>The salicylate, salsalate, increases the effect of the sulfonylurea, gliclazide.</td></tr><tr><td><a href="/drugs/DB01016">Glyburide</a></td><td>The salicylate, salsalate, increases the effect of the sulfonylurea, glibenclamide.</td></tr><tr><td><a href="/drugs/DB00741">Hydrocortisone</a></td><td>The corticosteroid, hydrocortisone, may decrease the effect of the salicylate, salsalate.</td></tr><tr><td><a href="/drugs/DB00703">Methazolamide</a></td><td>The salicylate, salsalate, at high dose increases the effect of the carbonic anhydrase inhibitor, methazolamide.</td></tr><tr><td><a href="/drugs/DB00563">Methotrexate</a></td><td>The salicylate, salsalate, increases the effect and toxicity of methotrexate.</td></tr><tr><td><a href="/drugs/DB00860">Prednisolone</a></td><td>The corticosteroid, prednisolone, may decrease the effect of the salicylate, salsalate.</td></tr><tr><td><a href="/drugs/DB00635">Prednisone</a></td><td>The corticosteroid, prednisone, may decrease the effect of the salicylate, salsalate.</td></tr><tr><td><a href="/drugs/DB01032">Probenecid</a></td><td>The salicylate, salsalate, decreases the uricosuric effect of probenecid.</td></tr><tr><td><a href="/drugs/DB00605">Sulindac</a></td><td>Risk of additive toxicity (e.g. bleed risk). Salsalate may decrease the serum concentration of sulindac. Consider alternate therapy or monitor for changes in the therapeutic effects of sulindac and adverse effects of both agents if the interacting agent is initiated, discontinued or dose changed.</td></tr><tr><td><a href="/drugs/DB01600">Tiaprofenic acid</a></td><td>Increased risk of gastrointestinal bleeding. </td></tr><tr><td><a href="/drugs/DB00500">Tolmetin</a></td><td>Additive effects increase the risk of GI bleeding. Monitor for increased bleeding risk during concomitant therapy. </td></tr><tr><td><a href="/drugs/DB00519">Trandolapril</a></td><td>The salicylate, Salsalate, may reduce the efficacy of Trandolapril. Monitor for changes in Trandolapril efficacy if Salsalate is initiated, discontinued or dose changed. </td></tr><tr><td><a href="/drugs/DB00374">Treprostinil</a></td><td>The prostacyclin analogue, Treprostinil, may increase the risk of bleeding when combined with the salicylate, Salsalate. Monitor for increased bleeding during concomitant thearpy. </td></tr><tr><td><a href="/drugs/DB00620">Triamcinolone</a></td><td>The corticosteroid, triamcinolone, may decrease the effect of the salicylate, salsalate.</td></tr></tbody></table></td></tr><tr><th>Food Interactions</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr></tbody></table>